☆ 4.8 Article

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

NEW ENGLAND JOURNAL OF MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai et al.

Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.

CELL (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Laura A. VanBlargan et al.

Summary: The emergence of the B.1.1.529 Omicron variant raises concerns about the efficacy of antibody countermeasures. This study shows that some of the antibodies currently in clinical use may lose their ability to neutralize the Omicron variant.

NATURE MEDICINE (2022)

添加到收藏夹

Article Immunology

The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States

Don Bambino Geno Tai et al.

Summary: The COVID-19 pandemic has disproportionately affected minority groups like African American, Native American, and LatinX communities with higher death rates. These disparities may be caused by biomedical factors and social determinants of health. Minority groups are more likely to have chronic medical conditions and lower access to healthcare, leading to worse COVID-19 outcomes.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

添加到收藏夹

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal et al.

Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Rebecca H. Haberman et al.

Summary: The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Ana C. Medeiros-Ribeiro et al.

Summary: In a large prospective phase 4 trial, vaccination with CoronaVac, an inactivated SARS-CoV-2 vaccine, elicited significantly lower virus-specific IgG antibodies and neutralizing antibodies in patients with autoimmune rheumatic diseases than in age- and sex-matched healthy control trial participants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Emma Pritchard et al.

Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

M. P. O'Brien et al.

Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Microbiology

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Jinhui Dong et al.

Summary: Structural analysis of two human monoclonal antibodies forming the antibody cocktail AZD7442, when bound to the RBD of SARS-CoV-2, demonstrates strong neutralization of variants of concern. Genetic and structural basis of neutralization has been defined, revealing crucial binding residues and positions of concern for virus escape. These germ line-encoded antibody features enable recognition of SARS-CoV-2 spike RBD and showcase the utility of cocktail AZD7442 in neutralizing emerging variant viruses.

NATURE MICROBIOLOGY (2021)

添加到收藏夹

Article Immunology

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines

Madhusudhanan Narasimhan et al.

Summary: Lung-transplant recipients are at high risk for COVID-19 due to their immunosuppressed state and the respiratory tropism of SARS-CoV-2. The study found that the serological response in LT patients after receiving two doses of COVID-19 vaccine is dampened, with Moderna vaccine showing a higher trend of seropositivity compared to Pfizer.

VACCINES (2021)

添加到收藏夹

Review Immunology

Neutralizing monoclonal antibodies for treatment of COVID-19

Peter C. Taylor et al.

Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Cross sectional investigation of a COVID-19 outbreak at a London Army barracks: Neutralising antibodies and virus isolation

Hannah Taylor et al.

Summary: The investigation at a London Army barracks during the early pandemic revealed a high rate of asymptomatic COVID-19 infections, with most seropositive individuals being found to have neutralizing antibodies and no infectious virus. Public health control measures were effective in mitigating spread, but the risk of virus re-introduction from asymptomatic carriers remains.

LANCET REGIONAL HEALTH-EUROPE (2021)

添加到收藏夹

News Item Critical Care Medicine

Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities

Tony Kirby

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

COVID-19 Among Workers in Meat and Poultry Processing Facilities ― 19 States, April 2020

Jonathan W. Dyal et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost et al.

NATURE MEDICINE (2020)

添加到收藏夹

Review Infectious Diseases

Monoclonal antibodies as anti-infective products: a promising future?

E. Pelfrene et al.

CLINICAL MICROBIOLOGY AND INFECTION (2019)

添加到收藏夹

Article Microbiology

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Gabriel J. Robbie et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

添加到收藏夹

Article Biochemical Research Methods

Structural characterization of a human Fc fragment engineered for lack of effector functions

Vaheh Oganesyan et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)

添加到收藏夹

Article Public, Environmental & Occupational Health

A modified Poisson regression approach to prospective studies with binary data

GY Zou

AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.